Quick Answer
Eloxx Pharmaceuticals, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $1.61M | -81.2% |
| 2022 | $8.56M | -28.7% |
| 2021 | $12.00M | +88.1% |
| 2020 | $6.38M | -39.3% |
| 2019 | $10.50M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $2.62M | -73.4% | -21.4% |
| June 30, 2023 | $3.33M | -70.0% | -17.2% |
| March 31, 2023 | $4.03M | -66.8% | -52.9% |
| December 31, 2022 | $8.56M | -28.7% | -13.2% |
| September 30, 2022 | $9.86M | -17.2% | -11.4% |
| June 30, 2022 | $11.13M | +206.0% | -8.2% |
| March 31, 2022 | $12.12M | +146.7% | +1.0% |
| December 31, 2021 | $12.00M | +88.1% | +0.7% |
- Over the 2019–2025 period, Eloxx Pharmaceuticals, Inc.’s long-term debt has declined by 100.0% (from $10.50 million to $0.00).
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: